{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:09:15Z","timestamp":1781276955722,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bayesian dose prediction software supports model-informed precision dosing to improve therapeutic outcomes. This study evaluated clinicians\u2019 awareness, usage, attitudes, and perceived barriers related to Bayesian dosing software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted using a validated electronic questionnaire distributed through eight international professional organizations. Descriptive statistics, non-parametric tests, and logistic regression analyses were performed using SPSS version 29.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 234 respondents, 190 (81.2%) were eligible and completed the survey. Most were from North America (67.4%), pharmacists (76.3%), and worked in academic hospitals (78.4%). Awareness of Bayesian dosing software was high (82.6%) among respondents, yet only 65% reported its use in clinical practice. The most used software included InsightRx (40.2%), DoseMe (22.5%), and MWPharm (18.6%), mainly for vancomycin (94.1%) and aminoglycosides (50%). The overall median attitude score (IQR) was 4.0 (2.0), indicating positive attitudes, whereas the barrier score was 3.0 (2.0), reflecting high implementation challenges. The most frequently reported barriers were prohibitive licensing costs (65%), lack of institutional support for use and maintenance (50.3%), and limited awareness of its use (49.7%). In multivariable analysis, \u201cregion\u201d was the sole predictor of awareness with participants from the Middle East significantly less aware (AOR = 0.14; 95% CI: 0.05\u20130.42; p = 0.002). Software type was significantly associated with professional role, with pharmacists more likely to select commonly used tools (AOR = 7.2; 95% CI: 1.4\u201317.9; p = 0.003). A non-significant negative correlation was observed between overall attitude and barrier scores (r = \u22120.49; p = 0.072).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite high awareness and positive attitudes toward Bayesian dosing software, its clinical use remains limited, primarily focused on vancomycin and aminoglycosides, mostly restricted to three commercial tools. Targeted interventions are required to address key implementation barriers related to licensing costs, institutional support, and awareness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1770100","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:35:33Z","timestamp":1777354533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Awareness, use, attitudes, and implementation challenges of Bayesian dose prediction software in clinical practice: a multi-organizational survey"],"prefix":"10.3389","volume":"17","author":[{"given":"Sarah S.","family":"Alghanem","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Kuwait University","place":["Kuwait City, Kuwait"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Downes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]},{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Philadelphia","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Desai","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.","place":["Northbrook, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean N.","family":"Avedissian","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Nebraska Medical Center","place":["Omaha, NE, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelmoneim","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Kuwait University","place":["Kuwait City, Kuwait"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","first-page":"66","article-title":"Performing content validation process in development of questionnaires","volume":"6","author":"Abdollahpour","year":"2011","journal-title":"Iran. J. Epidemiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/clpt.1991.86","article-title":"A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration","volume":"49","author":"Burton","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/pharmaceutics12070638","article-title":"What are the current approaches to optimising antimicrobial dosing in the intensive care unit?","volume":"12","author":"Chai","year":"2020","journal-title":"Pharmaceutics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.cmi.2022.03.041","article-title":"Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs","volume":"28","author":"Jager","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","article-title":"Model-informed precision dosing at the bedside: scientific challenges and opportunities","volume":"7","author":"Keizer","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/bcp.14066","article-title":"An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting","volume":"85","author":"Kumar","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1744-6570.1975.tb01393.x","article-title":"A quantitative approach to content validity","volume":"28","author":"Lawshe","year":"1975","journal-title":"Pers. Psychol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001424","article-title":"Economic evaluation of therapeutic drug monitoring and precision dosing in pediatrics: a short communication","author":"Lechuga-Noa","year":"2025","journal-title":"Ther. Drug Monit"},{"key":"B12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/oxfordjournals.aje.a115101","article-title":"The impact of confounder selection criteria on effect estimation","volume":"129","author":"Mickey","year":"1989","journal-title":"Am. J. Epidemiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0242-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/nur.20199","article-title":"Is the CVI an acceptable indicator of content validity? Appraisal and recommendations","volume":"30","author":"Polit","year":"2007","journal-title":"Res. Nurs. Health"},{"key":"B15","unstructured":"Raosoft sample size calculator\n          \n          \n          2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S583","DOI":"10.1093\/ofid\/ofz360.1463","article-title":"AUC24 vancomycin Bayesian-based dosing: increasing therapeutic target attainment with decreased TDM cost","volume":"6","author":"Sabourenkov","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B18","volume-title":"Clinical decision support software: guidance for industry and food and drug administration staff","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"B20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cpt.1679","article-title":"Development and implementation of electronic health record-integrated model-informed clinical decision support tools for the precision dosing of drugs","volume":"107","author":"Vinks","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s12913-022-07927-1","article-title":"Would they accept it? An interview study to identify barriers and facilitators to user acceptance of a prescribing advice service","volume":"22","author":"Yager","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/FTD.0000000000000750","article-title":"Therapeutic drug monitoring coupled with Bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: a prospective study and pharmacoeconomic analysis","volume":"42","author":"Zhang","year":"2020","journal-title":"Ther. Drug Monit."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1770100\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:35:40Z","timestamp":1777354540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1770100\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":22,"alternative-id":["10.3389\/fphar.2026.1770100"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1770100","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1770100"}}